The drug Venolife Duo is a modern combined venotonic and angioprotective drug in the form of tablets, which is used to eliminate and reduce the severity of signs of chronic venous diseases (CVD). Symptoms of this pathology include cramps, pain in the legs, a feeling of fullness, fatigue and heaviness in them. Venolife Duo tablets can be taken for up to a year according to the instructions. It is also used to treat acute and chronic hemorrhoids.
Venolife Duo tablets: instructions
The active components of Venolife Duo are hesperidin and diosmin. Thanks to micronization, the active ingredients are better absorbed by the body and act more actively, relieving the symptoms of varicose veins, such as pain, swelling, cramps and a feeling of heaviness in the legs1.
Venolife Duo helps reduce the distensibility of veins and stagnation in them, increases the ability of capillaries to maintain the integrity of the walls under mechanical stress and reduces their permeability. Clinical studies have proven the pharmacological activity of Venolife Duo tablets in relation to venous hemodynamics.
The drug increases the tone of the veins, reduces the time of emptying of the venous vessels. In people with impaired microcirculation, capillary resistance increased after taking Venolife Duo. The drug has shown its effectiveness in the treatment of CVD of the legs and in antihemorrhoidal treatment.
Venolife Duo
Dosage form Oval biconvex film-coated tablets, orange-pink in color. At the break, the tablet is light yellow to gray-yellow in color, with a heterogeneous structure. Marbling is allowed. Composition One tablet contains: active ingredient: Purified micronized flavonoid fraction (in terms of anhydrous substance), containing diosmin (90%) and other flavonoids (10%) - 500 mg excipients: gelatin, magnesium stearate, microcrystalline cellulose, carboxymethyl starch sodium, talc. Film coating: ready-mix “Vivacoat” [macrogol 6000, titanium dioxide, glycerol, magnesium stearate, hypromellose, red iron oxide dye, yellow iron oxide dye], sodium lauryl sulfate. Pharmacodynamics The combination of diosmin + hesperidin has venotonic and angioprotective properties. The drug reduces the distensibility of veins and venous stagnation, reduces capillary permeability and increases their resistance. The results of clinical studies confirm the pharmacological activity of the drug in relation to indicators of venous hemodynamics. A statistically significant dose-dependent effect of the drug was demonstrated for the following venous plethysmographic parameters: venous capacity, venous distensibility, venous emptying time. The optimal dose-effect ratio is observed when taking 1000 mg per day. The combination of diosmin + hesperidin increases venous tone: using venous occlusion plethysmography, a decrease in venous emptying time was shown. In patients with signs of severe microcirculation disorders, after treatment with the drug there was a (statistically significant compared to placebo) increase in capillary resistance, assessed by angiostereometry. The therapeutic effectiveness of the combination of diosmin + hesperidin in the treatment of chronic diseases of the veins of the lower extremities, as well as in the treatment of hemorrhoids, has been proven. Pharmacokinetics The main excretion of the drug occurs in the feces. On average, about 14% of the administered amount of the drug is excreted in the urine. The half-life is 11 hours. The drug undergoes active metabolism, which is confirmed by the presence of phenolic acids in the urine. Side effects Side effects of the diosmin + hesperidin combination observed during clinical studies were mild. Disorders of the gastrointestinal tract (diarrhea, dyspepsia, nausea, vomiting) were predominantly observed. While taking the combination of diosmin + hesperidin, the following side effects were reported, in the following gradation: very often (≥1/10), often (≥1/100, <1/10), infrequently (≥1/1,000, < .1/100), rare (≥1/10,000, <.1/1,000), extremely rare (<.1/10,000), unspecified frequency (frequency cannot be calculated from the available data). From the central nervous system: Rarely: dizziness, headache, general malaise. From the gastrointestinal tract: Often: diarrhea, dyspepsia, nausea, vomiting. Uncommon: colitis. Unspecified frequency: abdominal pain. From the skin: Rarely: skin rash, itching, urticaria. Unspecified frequency: isolated swelling of the face, lips, eyelids. In exceptional cases, angioedema. Inform your doctor if you experience any adverse reactions, including those not mentioned in this instruction, as well as changes in laboratory parameters during therapy. Features of sale Available without a prescription Special conditions - Before you start taking Venolife Duo, it is recommended to consult your doctor. — In case of exacerbation of hemorrhoids, the use of Venolife Duo does not replace the specific treatment of other anal disorders. The duration of treatment should not exceed the periods specified in the section “Method of administration and dosage”. If the symptoms do not disappear after the recommended course of therapy, you should be examined by a proctologist, who will select further therapy. — In the presence of venous circulation disorders, the maximum effect of treatment is ensured by combining therapy with a healthy (balanced) lifestyle: it is advisable to avoid long exposure to the sun, long periods of standing, and it is also recommended to reduce excess body weight. Walking and, in some cases, wearing special stockings help improve blood circulation. Contact your doctor immediately if your condition worsens or does not improve during treatment. Effect on the ability to drive vehicles, mechanisms. Clinical studies have not been conducted to study the effect of the combination of diosmin + hesperidin on the ability to drive a car and perform work requiring a high speed of mental and physical reactions. However, based on the available safety data, we can conclude that diosmin + hesperidin do not affect (do not have a significant effect) on these processes. Indications Venolife Duo is indicated for the treatment of symptoms of chronic venous diseases (elimination and relief of symptoms). Treatment of symptoms of venous-lymphatic insufficiency: - pain, - cramps of the lower extremities, - a feeling of heaviness and fullness in the legs, - “fatigue” of the legs. Treatment of manifestations of venous-lymphatic insufficiency: - edema of the lower extremities, - trophic changes in the skin and subcutaneous tissue, - venous trophic ulcers. Symptomatic treatment of acute and chronic hemorrhoids. Contraindications Hypersensitivity to the active substance or to the excipients included in the drug. The drug is not recommended for nursing women. Use during pregnancy and breastfeeding Pregnancy Experiments on animals did not reveal teratogenic effects. To date, there have been no reports of adverse effects when using the drug by pregnant women. Breastfeeding Due to the lack of data regarding the excretion of the drug in breast milk, taking the drug is not recommended for nursing women. Reproductive effects: Reproductive toxicity studies have shown no effects on reproductive function in rats of either sex. Drug interactions Clinical studies have not been conducted to study the interactions of the combination of diosmin + hesperidin with other drugs. To date, no cases of drug interactions have been reported.
Source: https://apteka.ru/catalog/venolayf-duo-0-5-n30-tabl-p-plen-oboloch-_5c951264c193e/ © Apteka.RU Dosage form Oval biconvex film-coated tablets, orange-pink color . At the break, the tablet is light yellow to gray-yellow in color, with a heterogeneous structure. Marbling is allowed. Composition One tablet contains: active ingredient: Purified micronized flavonoid fraction (in terms of anhydrous substance), containing diosmin (90%) and other flavonoids (10%) - 500 mg excipients: gelatin, magnesium stearate, microcrystalline cellulose, carboxymethyl starch sodium, talc. Film coating: ready-mix “Vivacoat” [macrogol 6000, titanium dioxide, glycerol, magnesium stearate, hypromellose, red iron oxide dye, yellow iron oxide dye], sodium lauryl sulfate. Pharmacodynamics The combination of diosmin + hesperidin has venotonic and angioprotective properties. The drug reduces the distensibility of veins and venous stagnation, reduces capillary permeability and increases their resistance. The results of clinical studies confirm the pharmacological activity of the drug in relation to indicators of venous hemodynamics. A statistically significant dose-dependent effect of the drug was demonstrated for the following venous plethysmographic parameters: venous capacity, venous distensibility, venous emptying time. The optimal dose-effect ratio is observed when taking 1000 mg per day. The combination of diosmin + hesperidin increases venous tone: using venous occlusion plethysmography, a decrease in venous emptying time was shown. In patients with signs of severe microcirculation disorders, after treatment with the drug there was a (statistically significant compared to placebo) increase in capillary resistance, assessed by angiostereometry. The therapeutic effectiveness of the combination of diosmin + hesperidin in the treatment of chronic diseases of the veins of the lower extremities, as well as in the treatment of hemorrhoids, has been proven. Pharmacokinetics The main excretion of the drug occurs in the feces. On average, about 14% of the administered amount of the drug is excreted in the urine. The half-life is 11 hours. The drug undergoes active metabolism, which is confirmed by the presence of phenolic acids in the urine. Side effects Side effects of the diosmin + hesperidin combination observed during clinical studies were mild. Disorders of the gastrointestinal tract (diarrhea, dyspepsia, nausea, vomiting) were predominantly observed. While taking the combination of diosmin + hesperidin, the following side effects were reported, in the following gradation: very often (≥1/10), often (≥1/100, <1/10), infrequently (≥1/1,000, < .1/100), rare (≥1/10,000, <.1/1,000), extremely rare (<.1/10,000), unspecified frequency (frequency cannot be calculated from the available data). From the central nervous system: Rarely: dizziness, headache, general malaise. From the gastrointestinal tract: Often: diarrhea, dyspepsia, nausea, vomiting. Uncommon: colitis. Unspecified frequency: abdominal pain. From the skin: Rarely: skin rash, itching, urticaria. Unspecified frequency: isolated swelling of the face, lips, eyelids. In exceptional cases, angioedema. Inform your doctor if you experience any adverse reactions, including those not mentioned in this instruction, as well as changes in laboratory parameters during therapy. Features of sale Available without a prescription Special conditions - Before you start taking Venolife Duo, it is recommended to consult your doctor. — In case of exacerbation of hemorrhoids, the use of Venolife Duo does not replace the specific treatment of other anal disorders. The duration of treatment should not exceed the periods specified in the section “Method of administration and dosage”. If the symptoms do not disappear after the recommended course of therapy, you should be examined by a proctologist, who will select further therapy. — In the presence of venous circulation disorders, the maximum effect of treatment is ensured by combining therapy with a healthy (balanced) lifestyle: it is advisable to avoid long exposure to the sun, long periods of standing, and it is also recommended to reduce excess body weight. Walking and, in some cases, wearing special stockings help improve blood circulation. Contact your doctor immediately if your condition worsens or does not improve during treatment. Effect on the ability to drive vehicles, mechanisms. Clinical studies have not been conducted to study the effect of the combination of diosmin + hesperidin on the ability to drive a car and perform work requiring a high speed of mental and physical reactions. However, based on the available safety data, we can conclude that diosmin + hesperidin do not affect (do not have a significant effect) on these processes. Indications Venolife Duo is indicated for the treatment of symptoms of chronic venous diseases (elimination and relief of symptoms). Treatment of symptoms of venous-lymphatic insufficiency: - pain, - cramps of the lower extremities, - a feeling of heaviness and fullness in the legs, - “fatigue” of the legs. Treatment of manifestations of venous-lymphatic insufficiency: - edema of the lower extremities, - trophic changes in the skin and subcutaneous tissue, - venous trophic ulcers. Symptomatic treatment of acute and chronic hemorrhoids. Contraindications Hypersensitivity to the active substance or to the excipients included in the drug. The drug is not recommended for nursing women. Use during pregnancy and breastfeeding Pregnancy Experiments on animals did not reveal teratogenic effects. To date, there have been no reports of adverse effects when using the drug by pregnant women. Breastfeeding Due to the lack of data regarding the excretion of the drug in breast milk, taking the drug is not recommended for nursing women. Reproductive effects: Reproductive toxicity studies have shown no effects on reproductive function in rats of either sex. Drug interactions Clinical studies have not been conducted to study the interactions of the combination of diosmin + hesperidin with other drugs. To date, no cases of drug interactions have been reported.
Source: https://apteka.ru/catalog/venolayf-duo-0-5-n30-tabl-p-plen-oboloch-_5c951264c193e/ © Apteka.RU Dosage form Oval biconvex film-coated tablets, orange-pink color . At the break, the tablet is light yellow to gray-yellow in color, with a heterogeneous structure. Marbling is allowed. Composition One tablet contains: active ingredient: Purified micronized flavonoid fraction (in terms of anhydrous substance), containing diosmin (90%) and other flavonoids (10%) - 500 mg excipients: gelatin, magnesium stearate, microcrystalline cellulose, carboxymethyl starch sodium, talc. Film coating: ready-mix “Vivacoat” [macrogol 6000, titanium dioxide, glycerol, magnesium stearate, hypromellose, red iron oxide dye, yellow iron oxide dye], sodium lauryl sulfate. Pharmacodynamics The combination of diosmin + hesperidin has venotonic and angioprotective properties. The drug reduces the distensibility of veins and venous stagnation, reduces capillary permeability and increases their resistance. The results of clinical studies confirm the pharmacological activity of the drug in relation to indicators of venous hemodynamics. A statistically significant dose-dependent effect of the drug was demonstrated for the following venous plethysmographic parameters: venous capacity, venous distensibility, venous emptying time. The optimal dose-effect ratio is observed when taking 1000 mg per day. The combination of diosmin + hesperidin increases venous tone: using venous occlusion plethysmography, a decrease in venous emptying time was shown. In patients with signs of severe microcirculation disorders, after treatment with the drug there was a (statistically significant compared to placebo) increase in capillary resistance, assessed by angiostereometry. The therapeutic effectiveness of the combination of diosmin + hesperidin in the treatment of chronic diseases of the veins of the lower extremities, as well as in the treatment of hemorrhoids, has been proven. Pharmacokinetics The main excretion of the drug occurs in the feces. On average, about 14% of the administered amount of the drug is excreted in the urine. The half-life is 11 hours. The drug undergoes active metabolism, which is confirmed by the presence of phenolic acids in the urine. Side effects Side effects of the diosmin + hesperidin combination observed during clinical studies were mild. Disorders of the gastrointestinal tract (diarrhea, dyspepsia, nausea, vomiting) were predominantly observed. While taking the combination of diosmin + hesperidin, the following side effects were reported, in the following gradation: very often (≥1/10), often (≥1/100, <1/10), infrequently (≥1/1,000, < .1/100), rare (≥1/10,000, <.1/1,000), extremely rare (<.1/10,000), unspecified frequency (frequency cannot be calculated from the available data). From the central nervous system: Rarely: dizziness, headache, general malaise. From the gastrointestinal tract: Often: diarrhea, dyspepsia, nausea, vomiting. Uncommon: colitis. Unspecified frequency: abdominal pain. From the skin: Rarely: skin rash, itching, urticaria. Unspecified frequency: isolated swelling of the face, lips, eyelids. In exceptional cases, angioedema. Inform your doctor if you experience any adverse reactions, including those not mentioned in this instruction, as well as changes in laboratory parameters during therapy. Features of sale Available without a prescription Special conditions - Before you start taking Venolife Duo, it is recommended to consult your doctor. — In case of exacerbation of hemorrhoids, the use of Venolife Duo does not replace the specific treatment of other anal disorders. The duration of treatment should not exceed the periods specified in the section “Method of administration and dosage”. If the symptoms do not disappear after the recommended course of therapy, you should be examined by a proctologist, who will select further therapy. — In the presence of venous circulation disorders, the maximum effect of treatment is ensured by combining therapy with a healthy (balanced) lifestyle: it is advisable to avoid long exposure to the sun, long periods of standing, and it is also recommended to reduce excess body weight. Walking and, in some cases, wearing special stockings help improve blood circulation. Contact your doctor immediately if your condition worsens or does not improve during treatment. Effect on the ability to drive vehicles, mechanisms. Clinical studies have not been conducted to study the effect of the combination of diosmin + hesperidin on the ability to drive a car and perform work requiring a high speed of mental and physical reactions. However, based on the available safety data, we can conclude that diosmin + hesperidin do not affect (do not have a significant effect) on these processes. Indications Venolife Duo is indicated for the treatment of symptoms of chronic venous diseases (elimination and relief of symptoms). Treatment of symptoms of venous-lymphatic insufficiency: - pain, - cramps of the lower extremities, - a feeling of heaviness and fullness in the legs, - “fatigue” of the legs. Treatment of manifestations of venous-lymphatic insufficiency: - edema of the lower extremities, - trophic changes in the skin and subcutaneous tissue, - venous trophic ulcers. Symptomatic treatment of acute and chronic hemorrhoids. Contraindications Hypersensitivity to the active substance or to the excipients included in the drug. The drug is not recommended for nursing women. Use during pregnancy and breastfeeding Pregnancy Experiments on animals did not reveal teratogenic effects. To date, there have been no reports of adverse effects when using the drug by pregnant women. Breastfeeding Due to the lack of data regarding the excretion of the drug in breast milk, taking the drug is not recommended for nursing women. Reproductive effects: Reproductive toxicity studies have shown no effects on reproductive function in rats of either sex. Drug interactions Clinical studies have not been conducted to study the interactions of the combination of diosmin + hesperidin with other drugs. To date, no cases of drug interactions have been reported.
Source: https://apteka.ru/catalog/venolayf-duo-0-5-n30-tabl-p-plen-oboloch-_5c951264c193e/ © Apteka.RU Venolife Duo film tablet 500 mg x60, ATX code: C05CA53 (Diosmin in combination with other drugs) Active substance: purified micronized flavonoid fraction (diosmin+flavonoids expressed as hesperidin) (micronised purified flavonoid fraction (diosmin+flavonoids expressed as hesperidin)) Group Group name
Dosage forms
Venolife, Duo
Film-coated tabletsreg. No.: LP-005215 dated 12/03/18 - Valid
Release form, packaging and composition
Film-coated tablets of orange-pink color, oval, biconvex, light yellow to gray-yellow in color at the break, heterogeneous structure, marbling is allowed.
1 tab.
purified micronized flavonoid fraction 500 mg
incl. diosmin flavonoids (in terms of hesperidin) 450 mg (90%) 50 mg (10%)
Excipients: gelatin, magnesium stearate, microcrystalline cellulose, sodium carboxymethyl starch, talc.
Film shell composition: ready-mix "Vivacoat" (macrogol 6000, titanium dioxide, glycerol, magnesium stearate, hypromellose, red iron oxide dye, yellow iron oxide dye), sodium lauryl sulfate.
10 pieces. — cellular contour packages (3) — cardboard packs. 10 pieces. — contour cell packaging (6) — cardboard packs.
Film-coated tablets of orange-pink color, oval, biconvex, scored on both sides, light yellow to gray-yellow in color at the break, heterogeneous structure, marbling is allowed.
1 tab.
purified micronized flavonoid fraction 1000 mg
including diosmin flavonoids (in terms of hesperidin) 900 mg (90%) 100 mg (10%)
Excipients: gelatin, magnesium stearate, microcrystalline cellulose, sodium carboxymethyl starch, talc.
Film shell composition: ready-mix "Vivacoat" (macrogol 6000, titanium dioxide, glycerol, magnesium stearate, hypromellose, red iron oxide dye, yellow iron oxide dye), sodium lauryl sulfate.
Clinical-pharmacological group: Venotonic and venoprotective drug Pharmaco-therapeutic group: Venotonic and venoprotective drug
Venolife Duo tablets: method of use
The release form of the drug is tablets 500 mg (30 pcs.) and 1000 mg (30 pcs.). They must be taken orally. For venous insufficiency, you need to drink 1000 mg of the drug per day, preferably during breakfast. The tablets must be swallowed with plenty of water. The score allows you to split the tablet in half for easier swallowing.
The optimal dose-effect ratio is observed when taking 1000 mg per day. The duration of treatment can be several months (up to 12 months). If symptoms recur, on the recommendation of a specialist, the course of treatment can be repeated.
Venolife Duo tablets ppo 1000 mg No. 30
Compound
Active ingredients: diosmin 900 mg, hesperidin 100 mg.
Pharmacokinetics
After oral administration, it undergoes active metabolism, which is confirmed by the presence of phenolic acids in the urine. It is excreted from the body mainly in feces. On average, about 14% of the dose taken is excreted in the urine. T1/2 is 11 hours.
Indications for use
Treatment of symptoms of venous-lymphatic insufficiency:
- pain;
- spasms of the lower extremities;
- feeling of heaviness and fullness in the legs;
- "tired" legs.
Treatment of manifestations of venous-lymphatic insufficiency:
- swelling of the lower extremities;
- trophic changes in the skin and subcutaneous tissue;
- venous trophic ulcers.
Symptomatic treatment of acute and chronic hemorrhoids.
Contraindications
Hypersensitivity to the active substance.
Directions for use and doses
The recommended dose for venous-lymphatic insufficiency is 1000 mg per day, preferably in the morning, during meals. The tablets should be swallowed with water. The score on the tablet is intended solely for scoring purposes to make it easier to swallow.
The duration of treatment can be several months (up to 12 months). In case of recurrence of symptoms, on the recommendation of a doctor, the course of treatment can be repeated.
The recommended dose for acute hemorrhoids is 3000 mg per day (1000 mg in the morning, afternoon and evening) for 4 days, then 2000 mg per day (1000 mg in the morning and evening) for the next 3 days.
The recommended dose for chronic hemorrhoids is 1000 mg per day.
Storage conditions
Store out of the reach of children at a temperature not exceeding 25 °C.
Best before date
2 years. Do not use after the expiration date.
special instructions
In case of exacerbation of hemorrhoids, the use of this drug does not replace the specific treatment of other anal disorders.
If symptoms do not disappear after the recommended course of therapy, you should be examined by a proctologist.
In the presence of venous circulation disorders, the maximum effect of treatment is ensured by combining therapy with a healthy (balanced) lifestyle: it is advisable to avoid long exposure to the sun, long periods of standing, and it is also recommended to reduce excess body weight. Walking and, in some cases, wearing special stockings helps improve blood circulation.
Description
Venotonic and venoprotective drug.
Dosage form
Orange-pink, oval, biconvex film-coated tablets; on the fracture from light yellow to gray-yellow color, heterogeneous structure; Marbling is allowed.
Action
A venotonic agent, it also has angioprotective properties. Reduces the distensibility of veins and venous stagnation, reduces capillary permeability and increases their resistance. The results of clinical studies confirm the pharmacological activity of drugs containing this active substance in relation to indicators of venous hemodynamics.
Increases venous tone: using venous occlusion plethysmography, a decrease in venous emptying time has been shown. In patients with signs of severe microcirculation disorders after therapy with drugs containing this active substance, there is a (statistically significant, compared to placebo) increase in capillary resistance, assessed by angiostereometry.
Therapeutic effectiveness has been proven in the treatment of chronic diseases of the veins of the lower extremities, as well as in the treatment of hemorrhoids.
Side effects
From the nervous system: rarely - dizziness, headache.
From the digestive system: often - diarrhea, dyspepsia, nausea, vomiting; infrequently - colitis; unspecified frequency - abdominal pain.
From the skin: rarely - rash, itching, urticaria; unspecified frequency - isolated swelling of the face, lips, eyelids; in exceptional cases - angioedema.
General reactions: rarely - general malaise.
Use during pregnancy and breastfeeding
To date, there have been no reports of adverse effects when used in pregnant women.
Use during breastfeeding is not recommended.
Interaction
Clinical studies have not been conducted to study the interactions of the combination of diosmin + hesperidin with other drugs.
To date, no cases of drug interactions have been reported.
Overdose
No cases of overdose have been described.
In case of drug overdose, seek medical help immediately.
Impact on the ability to drive vehicles and operate machinery
Clinical studies have not been conducted to study the effect of the combination of diosmin + hesperidin on the ability to drive a car and perform work that requires a high speed of mental and physical reactions. However, based on the available safety data, we can conclude that diosmin + hesperidin do not affect (do not have a significant effect) on these processes.
Contraindications and possible side effects
Taking the drug is contraindicated in case of hypersensitivity to the main active ingredients or auxiliary components that are present in the composition. It is not recommended to use the drug for women during lactation.
According to available data, side effects when taking drugs with diosmin and hesperidin were mild.
Mostly gastrointestinal disturbances were observed - vomiting, dyspepsia, nausea, diarrhea. Side effects such as dizziness, malaise, and headache rarely appeared. Before starting to take pills, you should consult a specialist. print version
